Navigation Links
Drive for good quality medicines, foods reinforced by USP agreements with Chinese drug authorities
Date:6/19/2009

Rockville, Md., June 19, 2009 As part of its efforts to improve the quality of medicines and food ingredients worldwide, the U.S. Pharmacopeial (USP) Convention this week reached three new cooperative agreements with Chinese drug control authorities. Because Chinese manufacturers supply so much of the world's drug and food ingredients, these agreementscoupled with three previous agreements between USP and other government organizations in Chinamark a significant commitment to ensure that concerns about quality are addressed. USP is a scientific, nonprofit organization that sets standards for the quality of prescription and over-the-counter drugs that are enforced by the U.S. Food and Drug Administration (FDA) in the United States. USP also sets standards for the quality of food ingredients and dietary supplements; these and USP's drug standards are used in more than 130 countries.

At a June 18 ceremony in Guangzhou, China, where he signed a Memorandum of Understanding (MOU) with the Guangzhou Municipal Institute of Drug Control, Roger L. Williams, M.D., USP's chief executive officer, said, "I am impressed at the energy and commitment of the Chinese people as they work to bring good quality medicines to consumers and patients in China and around the world. We are united in that goal." Mr. Yingqiao Jiang, head of the Guangzhou Institute, observed, "Chinese manufacturers share that commitment with regulatory bodies such as the Guangzhou Institute and organizations like USP. We are pleased to work together to help ensure the quality of medicines and their ingredients."

Earlier this week, USP also signed MOUs with the Beijing Municipal Institute of Drug Control and the Zhejiang Institute for Food and Drug Control. All are focused on strengthening the relationships through such initiatives as scientist exchange programs, joint standards- and testing-related work, and other projects to improve drug quality that will benefit from the expertise of both parties.

As a result of a 2008 agreement, USP and the Chinese Pharmacopoeia Commission (ChP) agreed this week to jointly develop standards for active pharmaceutical ingredients that have been singled out by the U.S. FDA and China State Food and Drug Administration (SFDA) as being especially important to help ensure quality medicines for patients and practitioners.

Based in the United States, USP has offices and laboratories in Shanghai, China; Hyderabad, India; and So Paulo, Brazil; USP also has offices in Basel, Switzerland. USP has formed similar partnerships in support of good quality medicines and food ingredients in these and other countries throughout the world.


'/>"/>

Contact: Francine Pierson
fp@usp.org
301-816-8588
US Pharmacopeia
Source:Eurekalert

Related medicine news :

1. Teamsters Call on United Way to Aid Frontline Blood Drive Workers
2. New Therapies, Including Novel Biologic Agents from Elan/Wyeth and Eli Lilly, Will Drive Robust 11 Percent Annual Growth In the Alzheimers Disease Market
3. Mom on Mission for Quality, Affordable Healthcare for All Drives Purple Bus Across Nation Gathering Stories
4. Pay Attention to Signs That Say Youre Too Tired to Drive
5. Screening Programs to Drive European GI Videoscope Market Despite Economic Downturn, According to Millennium Research Group
6. Availability of diagnostic tests drive success in hospitalist-run short-stay units
7. Advances in Medical Technology Identified as a Primary Driver of Increased Costs
8. Health Plans Prepare for Health Care Reform: Comparative Effectiveness, Consumerism Drive Future Changes, According to Deloitte Study
9. Sparta Systems Launches Hong Kong Operations to Drive Enterprise Quality and Compliance in Asia-Pacific Region
10. Record 73.4 Million Pounds Collected in Letter Carriers National Food Drive
11. Amgens Denosumab and Eli Lillys Forteo/Forsteo Will Drive Robust Annual Growth in the Osteoporosis Drug Market From 2013 to 2018
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/25/2016)... ... ... Austin residents seeking Mohs surgery services, can now turn to Dr. Jessica Scruggs ... for medical and surgical dermatology. , Dr. Dorsey brings specialization to include Mohs surgery, ... Micrographic Surgery completed by Dr. Dorsey was under the direction of Glenn Goldstein, MD, ...
(Date:6/25/2016)... Oklahoma City, Oklahoma (PRWEB) , ... June 25, ... ... to helping both athletes and non-athletes recover from injury. Recently, he has implemented ... for the Oklahoma City area —Johnson is one of the first doctors to ...
(Date:6/24/2016)... ... , ... June 19, 2016 is World Sickle Cell Observance Day. In an ... of holistic treatments, Serenity Recovery Center of Marne, Michigan, has issued a ... Cell Disease (SCD) is a disorder of the red blood cells, which can cause ...
(Date:6/24/2016)... ... June 24, 2016 , ... Comfort Keepers® of San ... Society and the Road To Recovery® program to drive cancer patients to and from ... adults to ensure the highest quality of life and ongoing independence. Getting to ...
(Date:6/24/2016)... Vegas, Nevada (PRWEB) , ... June 24, 2016 ... ... Las Vegas client, The Grove Investment Group (TGIG), has initiated cultivation and processing ... Grove, in Las Vegas and Pahrump, Nevada. , Puradigm is the manufacturer of ...
Breaking Medicine News(10 mins):
(Date:6/24/2016)...   Pulmatrix, Inc ., (NASDAQ: PULM ... announced today that it was added to the Russell ... comprehensive set of U.S. and global equity indexes on ... milestone for Pulmatrix," said Chief Executive Officer Robert ... progress in developing drugs for crucial unmet medical needs, ...
(Date:6/23/2016)... BEVERLY HILLS, Calif. , June 23, 2016 ... faced the many challenges of the current process. Many of ... option because of the technical difficulties and high laboratory costs ... would have to offer it at such a high cost ... to afford it. Dr. Parsa Zadeh , ...
(Date:6/23/2016)... 2016 Capricor Therapeutics, Inc. ... biotechnology company focused on the discovery, development and ... enrollment in its ongoing randomized HOPE-Duchenne clinical trial ... of its 24-patient target. Capricor expects the trial ... of 2016, and to report top line data ...
Breaking Medicine Technology: